Statistics of A randomized, double-blinded, placebo-controlled, multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and biological activity of ATyR1940 in adult patients with facioscapulohumeral muscular dystrophy (FSHD
